A Phase I trial for ADCE-T02 is expected in Australia in Q4 this year, with a Clinical Trial Notification submitted in Australia. Image Credit: eamesBot
The FDA has approved J&Js Rybrevant plus Lazcluze to treat patients with certain types of NSCLC. Credit: Nattakorn_Maneerat via Shutterstock. Johnson & Johnson’s (J&J) Rybrevant
MindBio Therapeutics Corp. reported durability data from Phase 2A clinical trials in depressed patients testing MB22001, MindBio’s proprietary self-administered take home microdose of Lysergic Acid
Toronto, Ontario–(Newsfile Corp. – August 19, 2024) – PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company“), a specialty pharmaceutical company focused on
Vancouver, Canada – Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (‘Clearmind’ or the ‘company’), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve
Pegtarazimod is being studied as a potential treatment to aGvHD patients after haematopoietic stem cell transplant where steroid therapy is ineffective. Image: Shutterstock / Gorodenkoff.
Emergent’s CEO said the company can increase supply by around 40 million doses if needed. Image credit: Shutterstock / Ralf Liebhold. Emergent BioSolutions said it
The top 20 biopharmaceutical companies demonstrated resilience during the second quarter (Q2) of 2024 as global markets and investor optimism improved with anticipation of a
A House committee is investigating whether brand drug companies are collaborating with the Chinese military when they run clinical trials in that country. “For over
A new observational study found that people taking Ozempic and Wegovy appeared to experience suicidal thoughts at a higher rate than people on other drugs,